pharmaphorum Podcast

For AI to truly revolutionise drug discovery, it must move beyond pattern recognition and predictive analytics to include causality, which is essential for technical and regulatory success in drug discovery.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Ben Sidders, chief scientific officer at Biorelate, a company leveraging advanced data science methods to transform the focus and impact of drug discovery and...

Radiopharmaceutical therapy has attracted increasing attention in the treatment of refractory diseases that are not sensitive to current therapies, such as in oncology.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Greg Piefer, founder and CEO of SHINE Technologies, a nuclear fusion company mastering more immediate applications of fusion – such as in producing cancer-fighting medicine.

Piefer provides an over...

The second annual HLTH Europe conference brought together health leaders, start-ups, investors, and developers from across the globe for a mid-year pulse check on where healthcare innovation stands today – and where it’s headed next.

Amid economic uncertainty and shifting regulatory priorities, pharma, health tech, and care delivery are all racing to prove value and scale innovation. In this special extended episode of the pharmaph...

In today's healthcare landscape, there is a pressing need for quantitative methodologies that include the patients' perspective in any treatment decision.

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Marc Buyse, founder of IDDI and One2Treat, and also co-founder of CluePoints, about his recent work as one of the editors of – and a chapter contributor to – the first edition of "𝘏𝘢𝘯𝘥𝘣𝘰𝘰𝘬 𝘰𝘧 𝘎𝘦𝘯𝘦𝘳...

At this year’s Veeva R&D and Quality Summit, it was revealed that Novo Nordisk and Veeva have entered into a new partnership for clinical development.

In this episode of the pharmaphorum podcast, web editor Nicole Raleigh spoke with Stephanie Bova, chief digital officer at Novo Nordisk, and Rik van Mol, SVP R&D and Quality at Veeva, about the partnership, Novo aiming to accelerate clinical trials and launches by uniting bus...

The JCA process was passed into law by the European Union in 2022. The Joint Clinical Assessment is a process that will systematically assess all available clinical evidence for new drugs. Rolled out in stages, starting with oncology drugs and advanced therapy medicinal products this year, it will be fully implemented by 2030.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Tommy Bramley, SVP of market access a...

Originally employed in atomic physics, mass spectrometry is now an indispensable tool in modern science, and importantly medical science.

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Melissa Sherman, CEO of MOBILion Systems, a company pioneering next-generation separation science, by innovating best-in-class instruments that deeply, accurately, and efficiently characterise complex molecules.

Sherman discusses...

Onsite at ASCO 2025 in Chicago, web editor Nicole Raleigh sat down with Dr Stacy Lindborg, CEO of IMUNON, to discuss the company’s oral presentation at the Congress from the Phase 2 OVATION 2 study of IMNN-001, an IL-12 immunotherapy, in women with newly diagnosed advanced ovarian cancer – since published in the peer-reviewed journal Gynecologic Oncology today.

Dr Lindborg shares her journey to her present role, the true potential ...

Osteosarcoma is an extremely challenging and often aggressive cancer that has particular treatment challenges due to location, changing genotypes, and high recurrence rates. It mostly affects children and young adults under 20 years of age.

In a new pharmaphorum podcast, web editor Nicole Raleigh spoke with Paul Romness, president and CEO of OS Therapies, a company focused on the identification, development, and commercialisation o...

In healthcare, some of the most meaningful innovations happen when the right people are brought together in the right place. True progress depends on systems and infrastructure designed to connect ideas, people, and expertise across sectors.

Citylabs 4.0, now open in the heart of Manchester’s Knowledge Quarter on the Oxford Road Corridor, was built with exactly that goal in mind. Bringing the NHS, academia, and life sciences organi...

Boehringer Ingelheim’s data presented at ASCO 2025 reflected the company’s broad pipeline and growing body of evidence supporting innovative therapies for various cancers.

In a pharmaphorum podcast recorded onsite at the Congress, web editor Nicole Raleigh spoke with Itziar Canamasas, global head of oncology at Boehringer Ingelheim, for a discussion of the unmet needs in oncology and some of the specifics of the company’s data pres...

Trends can be predicted, and trends can unfold. Here, Liz Beatty – co-founder and chief strategy of Inato – speaks to the beginnings of a new era in drug development brought on by key technological advances in AI.

Historically, large urban academic centres have conducted the majority of clinical trials, leading to such issues as inaccessibility, lack of representation, and intense competition for participants. With growing industry...

As has been widely reported on, immunisation rates, including for flu and RSV, have been falling – at a troubling rate – and diseases like whooping cough and measles have seen a worrying resurgence due to anti-vaxxers. And not just in the US.

In a new pharmaphorum podcast, Rebecca Catterick, General Manager for Vaccines, UK & Ireland, at Sanofi, discusses this decline in vaccination rates, as well as what can be done to turn th...

Early access programmes (EAPs) for novel medicines are an often-misunderstood strategy outside of western markets.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Cem Zorlular, CEO of Er-Kim Pharmaceuticals, a company that has been serving as a regional affiliate for pharma and biotech since 1981 in the CEE and Mediterranean.

Market access strategies in many international markets do not function the same way as...

With the FDA and EMA releasing their annual reports detailing novel drug approvals in 2024, a new pharmaphorum podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face in the year ahead.

Host Nicole Raleigh is joined by Cencora’s Sandra Anderson, SVP of International Commercialisation, and Chris Williams, SVP & International Managing Director a...

ISPOR 2025, the leading global conference for Health Economics and Outcomes Research (HEOR), takes place 13th-16th May and marks the 30th anniversary of the organisation.

Ahead of the event, web editor Nicole Raleigh spoke with Rob Abbott, CEO and executive director of ISPOR – the leading professional society for HEOR globally – about the ins and outs and trends of HEOR.

ISPOR’s mission is to advance HEOR excellence to improve dec...

President Donald Trump’s April 15th executive order, “Lowering Drug Prices by Once Again Putting Americans First”, contained a smorgasbord of policy proposals targeting a variety of industry stakeholders.

But how much legal force do these different elements have, and what are the concrete takeaways for pharma? To answer these questions and more, host Jonah Comstock once again welcomes Hogan Lovells attorney Alice Valder Curran to t...

It can take up to 15 years for a new drug to reach the market, and with only 20% of pharmaceutical professionals adopting AI, one thing is clear: innovation in drug development is lagging behind.

In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Andrew Stelzer, head of business development at Unlearn.AI, about how the real hurdle in clinical research lies in effectively integrating AI.

Stelzer discusses the need ...